Ildiko Lingvay, MD
Endocrinology, Diabetes & Metabolism · Dallas, TXNPI 1447216916
Payments from drug & device makers
Across 17,104 payments — averaging $480.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$5.8M
- Novo Nordisk$845K
- Boehringer Ingelheim$843K
- Sanofi US Services Inc.$223K
- Pfizer$138K
- Eli Lilly$78K
- plus $314K from 27 others
Across 4 payments — averaging $5908.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$19K
- Pfizer$4K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 16,591 | $5,770,371 |
| Novo Nordisk | 49 | $844,997 |
| Boehringer Ingelheim | 68 | $842,639 |
| Sanofi US Services Inc. | 37 | $223,236 |
| Pfizer | 32 | $137,702 |
| Eli Lilly | 118 | $77,909 |
| AstraZeneca | 12 | $28,107 |
| Medical Device Business Services, Inc. | 13 | $26,418 |
| Boehringer Ingelheim International GmbH | 11 | $24,139 |
| Sanofi-aventis U.S. LLC | 13 | $21,576 |
| Merck | 14 | $19,191 |
| F. Hoffmann-la Roche AG | 8 | $18,341 |
| Janssen Scientific Affairs, LLC | 14 | $17,989 |
| Astrazeneca UK Limited | 11 | $17,077 |
| Zealand Pharma A/s | 8 | $16,627 |
| AbbVie | 10 | $16,358 |
| Neurocrine Biosciences, Inc. | 9 | $15,656 |
| Genentech, Inc. | 7 | $15,648 |
| Regeneron | 18 | $14,659 |
| Amgen | 5 | $9,392 |
| Lilly USA, LLC | 27 | $9,293 |
| Zealand Pharma US, Inc. | 9 | $7,898 |
| Dexcom, Inc. | 3 | $6,827 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 1 | $6,677 |
| Astrazeneca AB | 2 | $4,948 |
| Shionogi Inc | 5 | $4,853 |
| Boston Scientific | 3 | $4,063 |
| Intercept Pharmaceuticals, Inc. | 1 | $3,850 |
| Johnson & Johnson | 1 | $1,960 |
| Bayer | 1 | $1,880 |
| Dr.reddy's Laboratories,inc. | 1 | $550 |
| GSK | 1 | $83 |
| Corcept Therapeutics | 1 | $59 |
How this compares
$8,210,971 in reported general payments places this provider in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Dallas
- Julio RosenstockDallas$24.9M
- Peter BresslerDallas$4.2M
- Steve FordanDallas$2.8M
- Pablo MoraDallas$2.1M
- Saleemah FahmiDallas$1.2M
- Priscilla HollanderDallas$1M
- Oksana HamidiDallas$1M
- Amy ShahDallas$953K
- Abhimanyu GargDallas$920K
- Michelle WelchShavano Park$17.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.